Klempner Keys in on the Pan-Tumor Potential of Seribantumab in NGR1+ Solid Tumors

Dr. Klempner provides insight into unmet needs in NRG1 fusion–positive solid tumors, the novelty of seribantumab, and the potential clinical implications of the ongoing CRESTONE study.